Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

CBRE — CBRE Group

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 2.65%
Profit Margins 3.11%
Return on Equity 15.6%
Return on Assets 2.72%
Free Float 0.29B
Short Int % Utilisation 1.86%

2.2 Growth

Metric Value
Revenue Growth 18.6%
Free Cash Flow 1.09B
EBITDA 22.25 (Ratio)
Enterprise Value 48.96B
EV/Revenue 1.16
EV/EBITDA 22.25

Revenue growth of 18.6% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 1.08%
Risk / Std Dev (Ann.)* 31.44%
1-Year Price Return* -3.82%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $152.86
52-Week Range $121.69 – $174.27
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $40.55B $35.77B
Net income Reported net income $1.16B $968.00M
Total assets Year-end reported balance $30.88B $24.38B
Shareholders’ equity Year-end reported balance $8.88B $8.41B
Net margin Net income ÷ revenue 2.85% 2.71%
Asset turnover Revenue ÷ total assets 1.3133x 1.4669x
Equity multiplier Total assets ÷ shareholders’ equity 3.4779x 2.8989x
ROE Net margin × asset turnover × equity multiplier 13.03% 11.51%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $40.55B
Prior annual revenue $35.77B
EBIT $1.29B
Tax rate 20.00%
NOPAT = EBIT × (1 − tax rate) $1.04B
Forecast start-growth basis 13.37%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $1.04B
Add: depreciation & amortisation $729.00M
Less: capital expenditure -$366.00M
Less/(add): working-capital cash-flow movement -$67.00M
Current unlevered FCFF $1.33B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 13.37% $1.17B $826.49M -$414.94M -$75.96M $1.51B $1.44B
2 10.65% $1.30B $914.54M -$573.00M -$84.05M $1.56B $1.34B
3 7.94% $1.40B $987.13M -$741.36M -$90.72M $1.56B $1.22B
4 5.22% $1.47B $1.04B -$909.34M -$95.46M $1.51B $1.07B
5 2.50% $1.51B $1.06B -$1.06B -$97.84M $1.41B $909.05M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 1.19
Cost of equity 11.27%
Pre-tax cost of debt 7.71%
WACC 10.31%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $18.55B
Implied terminal EV / EBITDA 6.28x
Terminal value as % of enterprise value 65.51%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $5.98B
Present value of terminal value $11.35B
Indicated enterprise value $17.33B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $17.33B
Less: gross interest-bearing debt $9.99B
Add: cash and equivalents $1.86B
Add: affiliate investments $0.00
Less: minority interests $748.00M
Indicated common equity value $8.46B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 300,751,541.00
Share-count basis reported diluted weighted-average shares
Current market price $148.99
DCF indicative value per share $28.12
Indicative value vs. market price -81.13%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 2/4 evidenced checks
Lynch-inspired balance-and-growth checks 3/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:26:00.219770 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -34.32% -25.03%
Adjusted R² 0.22 0.25
Annualised residual volatility 27.18% 26.49%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.79 (4.93) 1.08 (5.99)
Size (SMB) 0.88 (4.07) 0.85 (3.75)
Value (HML) 0.24 (1.31) -0.09 (-0.41)
Profitability (RMW) NM 0.45 (2.36)
Investment (CMA) NM 0.59 (1.79)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequitycbrereal-estatereal-estate-servicesnasdaq